Dexcom, Inc. (DXCM) — ESG & Values Scores

Environment story

Dexcom discloses minimal direct environmental metrics. Scope 1, Scope 2, and Scope 3 emissions are not reported in the 10-K or proxy materials provided. No net-zero target year is disclosed. The company states it is 'preparing for the European Union's Corporate Sustainability Reporting Directive (CSRD)' and references a 2025 sustainability report 'aligned to SASB and TCFD,' but specific emissions data, renewable energy percentage, and climate targets are absent from filed documents. The company manufactures in Arizona, Malaysia, and is building a facility in Ireland; no decarbonization initiatives or renewable power commitments are detailed. Environmental risks are acknowledged under 'Sustainability (including environmental, social and governance) regulations' in the Risk Factors summary, but no proactive mitigation is evidenced. Penalty applied for undisclosed Scope 3 emissions and missing net-zero target.

Criticisms on file

FDA Warning Letter (March 2025) – Manufacturing Quality and Compliance: Company received warning letter following FDA inspections of San Diego and Mesa facilities relating to non-conformities in manufacturing processes and quality management system.
Source: DXCM 10-K (Item 1 - Business, Manufacturing section and Risk Factors)
No disclosed environmental compliance violations or resource/water controversies identified in materials.
Source: DXCM 10-K and Proxy materials (comprehensive review)

Disclosed initiatives

CSRD Preparation

Company states it is 'preparing for the European Union's Corporate Sustainability Reporting Directive (CSRD)' and will disclose social, governance and environmental information per CSRD requirements.
2025 Sustainability Report

Company published disclosures aligned to Sustainability Accounting Standards Board (SASB) Index for Medical Equipment and Supplies and Task Force on Climate-Related Financial Disclosures (TCFD).

Demonstrates alignment with ESG frameworks but specific metrics not provided in filed documents.
Product Waste Reduction

G7 and G7 15 Day products feature 'less waste' with smaller plastic components and packaging compared to G6.

Incremental reduction in product-level waste.

Social story

Dexcom discloses limited workforce demographic data in proxy materials. Board composition shows 5 women out of 12 directors (42% female representation), meeting modern governance standards. Executive leadership diversity details are not fully disclosed; the proxy names 6 executive officers (3 of whom appear to be men based on names; 1 woman: Sadie Stern, EVP Chief Human Resources Officer; gender of 2 officers not determinable from names alone). CEO-to-median-worker pay ratio is not disclosed. No documented union-suppression activities or major strikes within 24 months are evident. The company operates in a highly regulated healthcare sector and emphasizes 'Listen, Think Big, Be Dependable, and Serve with Integrity' as core values. Supply-chain human rights disclosures are absent (no conflict minerals policy, modern slavery statement, or forced-labor audit disclosed). No evidence of active labor disputes. Penalty applied for insufficient executive/leadership diversity transparency and undisclosed supply-chain ethics audits.

Criticisms on file

No documented union relations, labor disputes, strikes, or NLRB complaints identified in proxy or 10-K.
Source: DXCM 10-K and Proxy materials (comprehensive review)
CEO-to-median-worker pay ratio not disclosed; insufficient executive compensation transparency for comparative analysis.
Source: DXCM Proxy Statement – Pay Ratio section absent; only named executive compensation disclosed.
No supply-chain human rights audit, conflict minerals policy, modern slavery statement, or forced-labor flag disclosed.
Source: DXCM 10-K (no human rights or supply-chain ethics section); Proxy materials (no ESG/human rights disclosure).

Disclosed initiatives

Board Diversity

Board includes 5 women directors: Dr. Euan Ashley, Rimma Driscoll, Renée Galá, Bridgette Heller, and diverse backgrounds in healthcare, technology, and finance.

42% female board representation; strengthens governance diversity.
Code of Conduct

Dexcom has adopted a Code of Conduct outlining values on ethical issues, business conduct standards, and compliance requirements for officers, directors and employees.

Provides ethical governance framework; compliance helpline available (third-party hosted, allows anonymous reporting).
Human Resources Leadership

Sadie Stern serves as Executive Vice President, Chief Human Resources Officer, indicating dedicated HR governance.

Dedicated executive role for workforce and people management.
Employee Training & Support

Annual privacy and security training for all employees; cybersecurity awareness training on threats, password hygiene, incident reporting.

Workforce development and risk mitigation.

Governance story

Dexcom demonstrates strong board independence: 11 of 12 directors are independent (92%), exceeding the 75% threshold. The company operates a single-class voting structure with no dual-class shares, supporting one-share-one-vote principles. Board committees are well-structured with independent leadership (Audit, Compensation, Nominating & Governance, Technology committees). Board meetings occurred 7 times in fiscal 2025 with 97% average attendance. The company has adopted robust governance policies including Code of Conduct, Insider Trading Policy with anti-hedging provisions, and a Clawback Policy for compensation recovery post-restatement. Lobbying expenditures are not disclosed in materials provided. The FDA warning letter (March 2025) represents a significant regulatory challenge related to manufacturing compliance, not a governance failure per se, but indicates control/oversight gaps. No antitrust, privacy fines, or SEC consent decrees are disclosed. Governance score penalized for missing lobbying-spend transparency and the manufacturing compliance warning letter reflecting operational control weaknesses.

Criticisms on file

FDA Warning Letter (March 2025) – Manufacturing Compliance: Issued following inspections of San Diego and Mesa facilities for non-conformities in manufacturing processes and quality management system. Indicates control and compliance gaps.
Source: DXCM 10-K (Item 1 - Manufacturing section; Risk Factors section 'Risks Related to Manufacturing')
Lobbying expenditure not disclosed in materials provided; transparency on political engagement activities limited.
Source: DXCM 10-K and Proxy materials (no lobbying spend section identified)
No antitrust proceedings, SEC enforcement actions, or financial fraud allegations disclosed.
Source: DXCM 10-K (Item 3 - Legal Proceedings section); Proxy materials (comprehensive review)

Disclosed initiatives

Board Independence & Structure

92% board independence (11 of 12 independent directors); Lead Independent Director (Mark Foletta) in place; four standing committees with independent leadership.

Strong independent governance; effective oversight of management.
Code of Conduct & Compliance Infrastructure

Comprehensive Code of Conduct adopted; third-party compliance helpline available for anonymous reporting; regular review by Nominating & Governance Committee.

Establishes ethical standards and accessible reporting mechanisms.
Insider Trading Policy with Anti-Hedging

Policy prohibits trading on material non-public information, hedging, short sales, and other derivative positions in company securities by directors, officers, and employees.

Mitigates insider trading risk and conflicts of interest.
Clawback Policy (August 2023)

Compensation recovery policy compliant with Dodd-Frank and Nasdaq rules; allows recovery of incentive-based compensation from officers in event of accounting restatement.

Enforces accountability for financial reporting accuracy.
Risk Oversight Governance

Board delegates specific risk oversight to committees: Audit (financial/compliance), Compensation (compensation risk), Nominating & Governance (ESG/enterprise risk), Technology (cybersecurity/IT).

Structured risk management across all material areas.
Cybersecurity & Privacy Governance

Technology Committee oversees cybersecurity; multidisciplinary Cybersecurity and Privacy Committee reports to Board; ISO/IEC 27001 certification of Information Security Management System (ISMS) by PRI Certification.

Third-party certified cybersecurity controls; comprehensive governance.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Dexcom, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Dexcom, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)